Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says

Executive Summary

Office of Prescription Drug Promotion is focused on most egregious issues where human safety is at stake; CDER's Woodcock also says that First Amendment issues are affecting enforcement.

Related Content

A Word Here, A Word There: IND Investigator Tweaks Blog After US FDA Untitled Letter
Ascend’s EstroGel Promotion Misrepresents Efficacy Compared To Other Products, US FDA Says
FDA's Promotional Reviews Decline, But Says It's Only Part Of Job
FDA Advertising Enforcement Highlighted By HHS Amid Drop In Citations
Off-Label Promotion Decisions Likely Made Case-by-Case, US FDA Official Says
First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Industry's Off-Label Hearing Priorities Taking Shape
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement
Internet Searching May Get ‘Riskier’ For Patients After FDA Citations


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts